Rectal and Bladder Dose Measurements in the Intracavitary Applications of Cervical Cancer Treatment with HDR Afterloading System: Comparison of TPS Data with MOSFET Detector

Background: Intracavitary brachytherapy plays a major role in management of cervical carcinoma. Assessment of dose received by OAR’s therefore becomes crucial for the estimation of radiation toxicities in HDR brachytherapy. Objective: Purpose of this study is to evaluate the role of in vivo dosimetry in HDR brachytherapy and to compare actual doses delivered to OAR’ s with those calculated during treatment planning. Material and Methods: In this retrospective study, 50 patients of cervical carcinoma were treated by Microselectron HDR. Out of 50 patients, 26 were treated with a dose of 7 Gy and 24 with a dose of 9 Gy, prescribed to point A. Brachytherapy planning and evaluation of dose to bladder and rectum was done on TPS in vivo dosimetry was performed using portable MOSFET. Results: Calibration factors calculated for both dosimeters are almost equal and are 0.984 cGy/mV and 1.0895 cGy/mV. For bladder, dose deviation was found to be within ± 5% in 28 patients, ± 510% in 14 patients, ± 1015% in 4 patients. Deviation between TPScalculated dose and dose measured by MOSFET for rectum was within ± 5% in 31 patients, ± 5–10% in 8 patients, and ± 10–15% in 7 patients. Conclusion: TPS calculated doses were slightly higher than that measured by MOSFET. The use of small size MOSFET dosimeter is an efficient method for accurately measuring doses in highdose gradient fields typically seen in brachytherapy. Therefore, to reduce the risk of large errors in dose delivery, in vivo dosimetry can be done in addition to TPS computations.